Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Granisetron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 12/20 | 1.00 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 1.00 |
| ▸ | SLC22A2 | O15244 | 1/20 | 1.00 |
| ▸ | HTR3B | O95264 | 1/20 | 1.00 |
| ▸ | CHRNB2 | P17787 | 1/20 | 1.00 |
| ▸ | CHRNA3 | P32297 | 1/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 1.00 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 1.00 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.91 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.91 |
| ▸ | TSHR | P16473 | 1/20 | 0.91 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.91 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.91 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Granisetron SCHEMBL4891 | 1.00 | HTR3A (1.00) | HTR3AHTR3ESLC22A2HTR3BCHRNB2 | |
| Granisetron SCHEMBL29372622 | 1.00 | HTR3A (1.00) | HTR3AHTR3ESLC22A2HTR3BCHRNB2 | |
| Granisetron SCHEMBL13660190 | 1.00 | HTR3A (1.00) | HTR3AHTR3ESLC22A2HTR3BCHRNB2 | |
| Granisetron SCHEMBL30372601 | 1.00 | HTR3A (1.00) | HTR3AHTR3ESLC22A2HTR3BCHRNB2 | |
| Granisetron SCHEMBL4109977 | 1.00 | HTR3A (1.00) | HTR3AHTR3ESLC22A2HTR3BCHRNB2 | |
| Granisetron SCHEMBL13287290 | 1.00 | HTR3A (1.00) | HTR3AHTR3ESLC22A2HTR3BCHRNB2 | |
| Granisetron SCHEMBL16642163 | 1.00 | HTR3A (1.00) | HTR3AHTR3ESLC22A2HTR3BCHRNB2 | |
| Granisetron SCHEMBL34178 | 1.00 | HTR3A (1.00) | HTR3AHTR3ESLC22A2HTR3BCHRNB2 | |
| Granisetron SCHEMBL4890 | 1.00 | HTR3A (1.00) | HTR3AHTR3ESLC22A2HTR3BCHRNB2 | |
| Granisetron SCHEMBL33433 | 0.99 | HTR3A (0.98) | HTR3AHTR3ESLC22A2HTR3BCHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040029972-A1 | Combination treatment for depression | HOWARD HARRY R (US) | 2004-02-12 | — | — | US | claimed |
| EP-1230921-A1 | Combination treatment for depression | Pfizer Products Inc. (US) | 2002-08-14 | — | — | EP | claimed |
| US-20020107244-A1 | An antidepressant formulation consists of a biphenoxy or binaphthelenoxy compound as antidepressant, a 5-HT3 receptor antagonist and a carrier | PFIZER PRODUCTS INC. | 2002-08-08 | — | — | US | claimed |
| US-20020035057-A1 | Treatment of movement disorders by administration of 5-hydroxytryptamine receptor/alpha2 adrenergic receptor antagonist compositions | RICHTER VIRGINIA PACT (US) | 2002-03-21 | — | — | US | claimed |
| EP-0323105-B1 | Process for the preparation of 3-methylindazole-3-carboxylic acid | BEECHAM GROUP PLC (GB) | 1999-10-20 | — | — | EP | claimed |
| EP-0559297-B1 | Use of heterocyclic derivatives for the manufacture of medicaments | GLAXO GROUP LTD (GB) | 1997-05-07 | — | — | EP | claimed |
| US-5530008-A | USEFUL FOR TREATING ANXIETY DISORDER AND AGORAPHOBIA | SANDOZ LTD. (CH) | 1996-06-25 | — | — | US | claimed |
| EP-0279512-B1 | Use of certain 5-HT3 receptor antagonists in the treatment of visceral pain | BEECHAM GROUP PLC (GB) | 1996-03-27 | — | — | EP | claimed |
| EP-0279114-B2 | Medicaments for the treatment or prevention of the withdrawal syndrome | GLAXO GROUP LTD (GB) | 1995-08-23 | — | — | EP | claimed |
| EP-0422154-B1 | THERAPEUTIC USE OF 5-HT3 RECEPTOR ANTAGONISTS | SANDOZ AG (AT) | 1993-12-01 | — | — | EP | claimed |
| US-4859709-A | Pharmaceutical composition | BEECHAM GROUP PLC (GB) | 1989-08-22 | — | — | US | claimed |
| EP-0323105-A1 | Novel process | BEECHAM GROUP PLC (GB) | 1989-07-05 | — | — | EP | claimed |
| US-4845092-A | OF VISCERAL PAIN IN MAMMALS, HUMANS | BEECHAM GROUP PLC (GB) | 1989-07-04 | — | — | US | claimed |
| EP-0279990-A2 | Use of heterocyclic derivatives in the treatment of cognitive disorders | GLAXO GROUP LIMITED (GB) | 1988-08-31 | — | — | EP | claimed |
| EP-0279512-A2 | Use of certain 5-HT3 receptor antagonists in the treatment of visceral pain | BEECHAM GROUP PLC (GB) | 1988-08-24 | — | — | EP | claimed |
| EP-0279114-A1 | Medicaments for the treatment or prevention of the withdrawal syndrome | GLAXO GROUP LIMITED (GB) | 1988-08-24 | — | — | EP | claimed |
| EP-0278173-A2 | Use of heterocyclic derivatives in the treatment of depressions | GLAXO GROUP LIMITED (GB) | 1988-08-17 | — | — | EP | claimed |
| WO-1988003801-A1 | MEDICAMENTS FOR TREATMENT OR PREVENTION OF WITHDRAWAL SYNDROME | GLAXO GROUP LIMITED (GB) | 1988-06-02 | — | — | WO | claimed |
| EP-0223385-A2 | 8-Azabicyclo[3,2,1]octane and 9-azabicyclo[3,3,1]nonane derivatives | BEECHAM GROUP PLC (GB) | 1987-05-27 | — | — | EP | claimed |
| EP-0200444-A2 | Azabicyclononyl-indazole-carboxamide having 5-HT antagonist activity | BEECHAM GROUP PLC (GB) | 1986-11-05 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107244-A1 | An antidepressant formulation consists of a biphenoxy or binaphthelenoxy compound as antidepressant, a 5-HT3 receptor antagonist and a carrier | HTR3A, HTR3E, HTR4 | HTR3A 1/4885HTR3E 2/4885SLC22A2 814/4885 |
| US-20040029972-A1 | Combination treatment for depression | HTR3A, HTR5A, HTR6 | HTR3A 1/4885HTR3E 7/4885SLC22A2 890/4885 |
| US-20020035057-A1 | Treatment of movement disorders by administration of 5-hydroxytryptamine receptor/alpha2 adrenergic receptor antagonist compositions | HTR2C, HTR2A, ADRA2C | HTR3A 8/4885HTR3E 28/4885SLC22A2 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.